MedTrace Logo

The Moran AMD Genetic Testing Assessment Study

NCT05265624 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-10-01

Study results available
· View outcomes & findings →

Summary

The goals of this study are:

To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.

Conditions

  • Age-Related Macular Degeneration
  • Genetic Testing
  • Nutritional Biomarkers

Interventions

BEHAVIORAL

Early disclosure of genetic testing results

Early disclosure group receives results of genetic testing at Month 1

BEHAVIORAL

Late disclosure of genetic testing results

Late disclosure group receives results of genetic testing at Month 12

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Paul S. Bernstein

    lead OTHER

Principal Investigators

  • Paul Bernstein, MD, PhD · University of Utah Moran Eye Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-03
Primary Completion
2024-07-12
Completion
2024-07-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05265624 on ClinicalTrials.gov